PF-06936308 / Pfizer - LARVOL DELTA

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC (clinicaltrials.gov) - P1 | N=36 | Terminated | Sponsor: Pfizer | Completed ➔ Terminated; The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology portfolio; the study was not terminated because of safety concerns.

Trial termination • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC (clinicaltrials.gov) - P1; N=36; Completed; Sponsor: Pfizer; Recruiting ➔ Completed

Clinical • Trial completion • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Pfizer; N=100 ➔ 36; Trial completion date: Dec 2023 ➔ Sep 2021; Trial primary completion date: Dec 2023 ➔ Sep 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC (clinicaltrials.gov) - P1; N=97; Recruiting; Sponsor: Pfizer; Trial completion date: Nov 2021 ➔ Dec 2023; Trial primary completion date: Nov 2021 ➔ Dec 2023

Clinical • Trial completion date • Trial primary completion date